Merck’s Tredaptive Does Not Lower Risk of Heart Attack

by Kathy Jones on  December 21, 2012 at 7:19 PM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

Global pharmaceutical giant Merck revealed that clinical trials have shown its drug is not effective in reducing the risk of heart attack despite lowering cholesterol.
 Merck’s Tredaptive Does Not Lower Risk of Heart Attack
Merck’s Tredaptive Does Not Lower Risk of Heart Attack

The drug, known as Tredaptive, does manage to lower bad cholesterol and raise good cholesterol levels and is currently used in more than 40 countries though it is not available in the United States.

Merck conducted a four-year long study involving more than 25,000 volunteers and found that the drug did not reduce the risk of heart attacks.

The company revealed that it will be recommending doctors not to prescribe the drugs for new patients and added that it will be working closely with regulatory agencies to determine what its next step should be. Tredaptive generated over $13 million for Merck over the first three quarters of the year and shares of the company fell by 3.4 percent in Thursday's trading.



Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Chest Pain Cardiac Catheterization Heart Attack Diet Lifestyle and Heart Disease Stress and the Gender Divide Heart Heart Attack- Lifestyle Risks Healthy Heart Hyperventilation Statins 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive